Nimbus Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
130 Prospect St Ste 301, Cambridge, Mass...Phone Number
(857) 999-2009Website
www.nimbustx.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Nimbus Therapeutics
Nimbus Therapeutics specializes in the design and development of highly selective small molecule medicines aimed at improving patient outcomes in oncology, immunology, and metabolic diseases. The company employs advanced computational drug design and a meticulous approach to target selection, ensuring their products are both effective and innovative. With a strong track record of success, Nimbus is committed to pushing the boundaries of medicine through cutting-edge technologies and world-class expertise. Their intended clients include patients in need of novel treatments and healthcare partners seeking collaboration in drug development.Explore more
Nimbus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nimbus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Nimbus Therapeutics recently announced quarterly report
Check if Nimbus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Nimbus Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Nimbus Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Nimbus Therapeutics
Nimbus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Nimbus Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Nimbus Therapeutics launches new products
Recommended Actions
Find VP level buyers at Nimbus Therapeutics
Find more new buyers
Compare Similar Companies to Nimbus Therapeutics
Compare insights from companies similar to Nimbus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nimbus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nimbus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nimbus Therapeutics.
Nimbus Therapeutics financials insights
Gather financial insights about Nimbus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$1.5M
Series A
$24M
2015
Series B
$43M
2018
Unspecified
$65M
2020
Private Equity
$60M
2021
Private Equity
$105M
2022
Other Financing Round
$125M
2023
Other Financing Round
$210M
Nimbus Therapeutics Tech Stack
A closer look at the technologies used by Nimbus Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Artificial Intelligence
Person-Based
Person-Based
Pharmaceuticals
Person-Based
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Nimbus Therapeutics News & Media
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the appointment of Abbas Kazimi, MS, as Chief Executive Officer and a member of the Board of Directors, effective immediately. He succeeds Jeb Keiper, MS, MBA, who has stepped down from the position as part of a planned transition. “We are excited to aNimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the achievement of a significant preclinical milestone. This milestone, achieved in collaboration with Eli Lilly and Company (Lilly), targets a specific isoform of AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases. AMPK,Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the advancement of its clinical oncology therapeutic pipeline, and the appointment of Peter J. Tummino, Ph.D., to President of Research and Development. Dr. Tummino will be responsible for advancing the company’s product portfolio through all phases ofNimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the presentation of new clinical and translational data from its ongoing Phase 1/2 trial of NDI-101150, a novel, oral, potent and selective small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, for the treatment of advanced solid tumors. R
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding Nimbus Therapeutics
Sign Up For FreeTo access detailed company insights
Nimbus Therapeutics specializes in the design and development of highly selective small molecule medicines aimed at improving patient outcomes in oncology, immunology, and metabolic diseases. The company employs advanced computational drug design and a meticulous approach to target selection, ensuring their products are both effective and innovativ... Read More
